The efficacy and safety of sublingual immunotherapy (SLIT) in house dust mite-induced allergic asthma (AA) have yet to be firmly established, especially in adult patients. Our objective is to evaluate the efficacy of SLIT with Dermatophagoides farinae drops in adult patients with AA.
One hundred and thirty-four adult patient data with house dust mite (HDM)-induced AA who had been treated for 2 years were collected. These patient data that we collected were divided into the SLIT group (n = 85) and control group (n = 49). All patients were treated with low to moderate dose of inhaled glucocorticoid and long-acting β2 agonists. Patients in the SLIT group were further treated with D. farinae drops. Clinical scores including the total asthma symptom score (TASS), total asthma medicine score (TAMS), asthma control test (ACT), and peak flow percentage (PEF%) were assessed before treatment and at yearly visits. The presence of adverse events (AEs) were recorded once a month.
Before treatment, the PEF% in the SLIT group was significantly lower than that in the control group (p < 0.05). After 2 years, both treatments were effective in the clinical scores when compared with baseline values (all p < 0.001). Meanwhile, the SLIT group showed significantly lower TASS and TAMS (all p < 0.001) and higher ACT (p < 0.001) and PEF% (p < 0.05) when compared with the control group. No severe systemic AEs were reported.
SLIT with D. farinae drops plus pharmacotherapy is more effective than routine drug treatment in adult patients with AA.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Yukselen A, Kendirli SG (2014) Role of immunotherapy in the treatment of allergic asthma. World J Clin Cases: WJCC 2(12):859. 10.12998/wjcc.v2.i12.859
The global asthma report 2014. Available at: http://www.globalasthmareport.org/burde-n/burden.php
Masoli M, Fabian D, Holt S et al (2004) Global burden of asthma. Allergy 59:469–478
Knudsen TB, Thomsen SF, Nolte H et al (2009) A population-based clinical study of allergic and non-allergic asthma. J Asthma 46:91–94. https://doi.org/10.1080/02770900802524657
Zureik M, Neukirch C, Leynaert B et al (2002) Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community Respiratory Health Survey. BMJ 325:411–414
Masoli M, Fabian D, Holt S et al (2004) The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 59:469–478. https://doi.org/10.1111/j.1398-9995.2004.00526.x
Li J, Sun B, Huang Y et al (2009) A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy 64:1083–1092. https://doi.org/10.1111/j.1398-9995.2009.01967.x
Platts-Mills TAE, Erwin EA, Heymann PW et al (2009) Pro: the evidence for a causal role of dust mites in asthma. Am J Respir Crit Care Med 180:109–121. https://doi.org/10.1164/rccm.200811-1756PR
Li J, Sun B, Huang Y et al (2009) A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy 64(7):1083–1092. https://doi.org/10.1111/j.1398-9995.2009.01967.x
Lind P, Hansen OC, Horn N (1988) The binding of mouse hybridoma and human IgE antibodies to the major fecal allergen, der p I, of Dermatophagoides pteronyssinus. Relative binding site location and species specificity studied by solid-phase inhibition assays with radiolabeled antigen. J Immunol 140(12):4256–4262
Thomas WR, Smith WA, Hales BJ et al (2002) Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 129(1):1
Yasueda H, Mita H, Yui Y et al (1989) Comparative analysis of physicochemical and immunochemical properties of the two major allergens from Dermatophagoides pteronyssinus and the corresponding allergens from Dermatophagoides farinae. Int Arch Allergy Appl Immunol 88(4):402–407
Bousquet J, Lockey R, Malling HJ (1998) World Health Organization position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53(Suppl. 44):1–42
Akdis CA, Akdis M (2011) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127:18–27
Akdis CA (2012) Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 18:736–749
Calamita Z, Saconato H, Pela AB et al (2006) Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane collaboration method. Allergy 61:1162–1172. https://doi.org/10.1111/j.1398-9995.2006.01205.x
Compalati E, Passalacqua G, Bonini M et al (2009) The efficacy of sublingual immunotherapy for house dust mite respiratory allergy: results of a GA2LEN meta-analysis. Allergy 64:1570–1579. https://doi.org/10.1111/j.1398-9995.2009.02129.x
Canonica GW, Bousquet J, Casale T et al (2009) Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 64(Suppl. 91):1–59. https://doi.org/10.1111/j.1398-9995.2009.02309.x
Radulovic S, Wilson D, Calderon M et al (2011) Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66:740–752. https://doi.org/10.1111/j.1398-9995.2011.02583.x
Global Initiative for Asthma (GINA) Executive Committee (2006) Global strategy for asthma management and prevention 1–110
Wang H, Lin X, Hao C et al (2006) A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 61:191–197. https://doi.org/10.1111/j.1398-9995.2005.00913.x
Pfaar O, Demoly P, Gerth van Wijk R et al (2014) Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy 69(7):854–867. https://doi.org/10.1111/all.12383
Schlosser RJ, Smith TL, Mace J et al (2016) Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy. https://doi.org/10.1111/all.13048
Abramson MJ, Puy RM, Weiner JM (1995) Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 151:969–974. https://doi.org/10.1164/ajrccm.152.5.7582321
Ross RN, Nelson HS, Finegold I (2000) Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 22:329–341. https://doi.org/10.1016/S0149-2918(00)80037-5
Pifferi M, Baldini G, Marrazzini G et al (2002) Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy 57:785–790
Basomba A, Tabar AI, de Rojas DH et al (2002) Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 109:943–948
García-Robaina JC, Sánchez I, de la Torre F et al (2006) Successful management of mite-allergicasthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 118:1026–1032. https://doi.org/10.1016/j.jaci.2006.07.043
Wang L, Yin J, Fadel R et al (2014) House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 69(9):1181–1188. https://doi.org/10.1111/all.12188
Mosbech H, Deckelmann R, De Blay F et al (2014) Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 134:568–575. https://doi.org/10.1016/j.jaci.2014.03.019
Virchow JC (2016) Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma. JAMA 315:1715–1725. https://doi.org/10.1001/jama.2016.3964
Shao J, Cui YX, Zheng YF et al (2014) Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. Am J Rhinol Allergy 28(2):131. https://doi.org/10.2500/ajra.2014.28.4006
Li P, Li Q, Huang Z et al (2014) Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases[C]. Int Forum Allergy Rhinol. https://doi.org/10.1002/alr.21397
Keles S, Karakoc-Aydiner E, Ozen A et al (2011) A novel approach inallergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 128:808–815. https://doi.org/10.1016/j.jaci.2011.04.033
Dahl R, Stender A, Rak S (2006) Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 61:185–190. https://doi.org/10.1111/j.1398-9995.2005.00949.x
Moral A, Moreno V, Girón F et al (2016) Adverse reactions and tolerability of high-dose sublingual allergen immunotherapy. J Asthma Allergy 9:129–133. https://doi.org/10.2147/JAA.S107830
We thank the patients for their availability in taking part in this trial.
All financial supports for this clinical trial were provided by the Department of Science and Technology project of Wuzhou City, Guangxi Province, China (Contract No. 201202081).
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Zhong, C., Yang, W., Li, Y. et al. Clinical evaluation for sublingual immunotherapy with Dermatophagoides farinae drops in adult patients with allergic asthma. Ir J Med Sci 187, 441–446 (2018). https://doi.org/10.1007/s11845-017-1685-x
- Adult patient
- Allergic asthma
- Sublingual immunotherapy